The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Boehringer Ingelheim

Monday Biotech Deal Review: November 14, 2011

Welcome to your Monday Biotech Deal Review for November 14, 2011, marking the end of its one month hiatus.  The Monday Biotech Deal Review will now be resuming its normal weekly schedule.  Below are summaries of recent transactions over the past month, which includes the acquisition of Afexa by Valeant for $0.85 per Afexa share, in cash.    Read on to learn more.  Read more of this post

Trends Update — Personalized Medicine: DxS’ Latest Companion Diagnostics Deal

B&W_DNA_sequenceAs personalized medicine inches toward becoming the standard of care for cancer, the question of who pays for the genotyping becomes more important.  A deal announced Friday between DxS, a molecular diagnostics company, and Boehringer Ingelheim suggests that pharma companies will end up footing at least part of the bill by paying for the development (and marketing?) of companion diagnostics.

As noted by IVB in their Deals of the Week this week, the Boehringer Ingelheim deal is only one of several that DxS has done recently:

Last December, DxS signed a US-centered deal with Amgen to provide a companion diagnostic for the Big Biotech’s colorectal therapeutic Vectibix. The test maker’s so-called TheraScreen K-RAS test is already on the market in the EU and is used to help doctors determine which patients are unlikely to respond well to anti-EGFR therapies such as Bristol-Myers Squibb/ImClone’s Erbitux (cetuximab) and Amgen’s Vectibix. Moreover, DxS and Amgen have collaborated since last year on selling TheraScreen K-RAS alongside Vectibix in Europe, where the drug is cleared for patients with refractory metastatic colorectal cancer in which there is no K-RAS mutation.

Also notable: this statement in the press release attributed to Dr. Manfred Haehl, Corporate Senior Vice President Medicine of Boehringer Ingelheim…

As this year’s theme at ASCO highlights, it is very likely that personalised medicine will play an important role in selecting the most effective treatment for patients with cancer.

Bookmark and Share

Follow

Get every new post delivered to your Inbox.

Join 129 other followers